Takeda Pharmaceutical Company Limited
4502.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.51 | -0.82 | 0.55 | -0.61 |
| FCF Yield | 10.93% | 7.15% | 10.91% | 16.42% |
| EV / EBITDA | 10.49 | 12.68 | 9.61 | 9.04 |
| Quality | ||||
| ROIC | 3.14% | 4.02% | 4.69% | 4.11% |
| Gross Margin | 53.59% | 54.53% | 57.07% | 57.26% |
| Cash Conversion Ratio | 8.92 | 4.44 | 2.77 | 4.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.39% | 6.11% | 7.99% | 2.74% |
| Free Cash Flow Growth | 63.84% | -36.88% | -17.97% | 13.11% |
| Safety | ||||
| Net Debt / EBITDA | 4.31 | 5.67 | 3.91 | 3.80 |
| Interest Coverage | 3.36 | 3.46 | 4.83 | 4.31 |
| Efficiency | ||||
| Inventory Turnover | 1.75 | 1.60 | 1.75 | 1.79 |
| Cash Conversion Cycle | 213.80 | 227.25 | 205.11 | 207.42 |